ArticleMolecular cancer research : MCR2020
Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer.Breast cancer research : BCR · 2025Article
- Immune evasion and resistance in breast cancer.American journal of cancer research · 2025Review
- Cyclophilin A: promising target in cancer therapy.Cancer biology & therapy · 2024Review
- A novel role for the peptidyl-prolyl cis-trans isomerase Cyclophilin A in DNA-repair following replication fork stalling via the MRE11-RAD50-NBS1 complex.EMBO reports · 2024Article
- Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers.Molecules (Basel, Switzerland) · 2024Review
- Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer.Scientific reports · 2023Article
- Cyclophilin A binds to AKT1 and facilitates the tumorigenicity of Epstein-Barr virus by mediating the activation of AKT/mTOR/NF-κB positive feedback loop.Virologica Sinica · 2022Article
- Clinical and Prognostic Value ofCells · 2022Article
- Cyclophilin a represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein.Cell cycle (Georgetown, Tex.) · 2022Article
- Cyclophilin A/CD147 Interaction: A Promising Target for Anticancer Therapy.International journal of molecular sciences · 2022Review
- Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents.Drug discovery today · 2022Review
- Lipid-induced monokine cyclophilin-A promotes adipose tissue dysfunction implementing insulin resistance and type 2 diabetes in zebrafish and mice models of obesity.Cellular and molecular life sciences : CMLS · 2022Article
- Ubiquitin-specific peptidase 2 inhibits epithelial-mesenchymal transition in clear cell renal cell carcinoma metastasis by downregulating the NF-κB pathway.Bioengineered · 2022Article
- A Critical Role of Peptidylprolyl Isomerase A Pseudogene 22/microRNA-197-3p/Peptidylprolyl Isomerase A Axis in Hepatocellular Carcinoma.Frontiers in genetics · 2021Article
- Circular RNA circ_0084927 regulates proliferation, apoptosis, and invasion of breast cancer cells via miR-142-3p/ERC1 pathway.American journal of translational research · 2021Article
- Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Viralkumar Davra *Department of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.
Tamjeed SalehDepartment of Structural Biology, St Jude Children's Research Hospital, Memphis, Tennessee.
Ke GengDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.
Stanley KimaniDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.
Dhriti MehtaDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.
Canan KasikaraDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.
Brendan SmithDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.ORCID 0000-0002-3264-9248
Nicholas W ColangeloDepartment of Radiology, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.
Bryan CiccarelliDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.ORCID 0000-0002-7461-8925
Hong LiCenter for Advanced Proteomics, Rutgers University, Newark, New Jersey.
Edouard I AzzamDepartment of Radiology, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey.ORCID 0000-0002-8968-1142
Charalampos G KalodimosDepartment of Structural Biology, St Jude Children's Research Hospital, Memphis, Tennessee.
Raymond B BirgeDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey. sushil_kumar@dfci.harvard.edu birgera@njms.rutgers.edu.
Sushil Kumar *Department of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers- New Jersey Medical School, Newark, New Jersey. sushil_kumar@dfci.harvard.edu birgera@njms.rutgers.edu.
Rutgers, The State University of New Jersey · USSt. Jude Children's Research Hospital · USAbterra Biosciences (United States) · US
Funding
Rutgers Mass Spectrometry Core for Integrative Neuroscience ResearchP30NS046593 · NINDS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI LOBEL, PETER · 2004 to 2018
$9.9MStructure and functional mechanisms of molecular chaperones and protein kinasesR35GM122462 · NIGMS · UNIVERSITY OF MINNESOTA · PI CHARALAMPOS KALODIMOS · 2017 to 2026
$6.8MStructural insight into novel mechanisms of type III secretionR01AI094623 · NIAID · UNIVERSITY OF MINNESOTA · PI KALODIMOS, CHARALAMPOS · 2012 to 2023
$4.0MAllosteric and Transport Mechanisms in TonB-dependent TransportersR01AI121858 · NIAID · UNIVERSITY OF MINNESOTA · PI KALODIMOS, CHARALAMPOS · 2016 to 2020
$2.1MNon-canonical Signal Pathway for Crk in Breast CancerR01CA165077 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI BIRGE, RAYMOND B. · 2012 to 2016
$1.7MOrbitrap Fusion Lumos Tribrid MS System for Proteomics Research at Rutgers Newark CampusS10OD025047 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI LI, HONG · 2018 to 2018
$1.1MNCI NIH HHS R01 CA165077NIAID NIH HHS R01 AI094623NIAID NIH HHS R01 AI121858NIGMS NIH HHS R35 GM122462NIH HHS S10 OD025047NINDS NIH HHS P30 NS046593
Abstract
The Crk adaptor protein, a critical modifier of multiple signaling pathways, is overexpressed in many cancers where it contributes to tumor progression and metastasis. Recently, we have shown that Crk interacts with the peptidyl prolyl cis-trans isomerase, Cyclophilin A (CypA; PP1A) via a G
Indexed as
AnimalsAntineoplastic Agents, ImmunologicalBreast NeoplasmsCell HypoxiaCell Line, TumorCell MovementCyclosporineDrug SynergismFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsMiceModels, MolecularNeoplasm MetastasisalisporivirAntineoplastic Agents, ImmunologicalCRK protein, humanCyclosporineImmune Checkpoint InhibitorsPeptidylprolyl IsomerasePPIA protein, humanProto-Oncogene Proteins c-crk
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.